Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy, Journal of Clinical Oncology, vol.27, issue.22, pp.3677-3683, 2009. ,
DOI : 10.1200/JCO.2008.20.5278
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial, Journal of Clinical Oncology, vol.27, issue.19, pp.3109-3116, 2009. ,
DOI : 10.1200/JCO.2008.20.6771
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07, Journal of Clinical Oncology, vol.25, issue.16, pp.2198-2204, 2007. ,
DOI : 10.1200/JCO.2006.08.2974
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, The Lancet, vol.355, issue.9209, pp.1041-1047, 2000. ,
DOI : 10.1016/S0140-6736(00)02034-1
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.343, issue.13, p.905, 2000. ,
DOI : 10.1056/NEJM200009283431302
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, The Lancet, vol.352, issue.9138, pp.1413-1418, 1998. ,
DOI : 10.1016/S0140-6736(98)02309-5
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer, The Lancet, vol.352, issue.9138, pp.1407-1412, 1998. ,
DOI : 10.1016/S0140-6736(98)03085-2
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.14, pp.2311-2319, 2008. ,
DOI : 10.1200/JCO.2007.13.1193
URL : https://hal.archives-ouvertes.fr/inserm-00484211
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2, p.229, 2004. ,
DOI : 10.1200/JCO.2004.05.113
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients, British Journal of Cancer, vol.24, issue.9, pp.1287-1292, 2006. ,
DOI : 10.1016/S0959-8049(98)00353-0
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study, Annals of Oncology, vol.20, issue.6, pp.1042-1047, 2009. ,
DOI : 10.1093/annonc/mdn730
A Retrospective Study of Bifractionated CPT-11 With LF5FU Infusion (FOLFIRI-3) in Colorectal Cancer Patients Pretreated With Oxaliplatin and CPT-11 Containing Chemotherapies, American Journal of Clinical Oncology, vol.31, issue.1, pp.89-94, 2008. ,
DOI : 10.1097/COC.0b013e318134ee9c
URL : https://hal.archives-ouvertes.fr/inserm-00483393
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004. ,
DOI : 10.1056/NEJMoa032691
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy, British Journal of Cancer, vol.63, issue.9, pp.1407-1414, 2010. ,
DOI : 10.1038/nm988
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity, Cancer Res, vol.49, pp.1465-1469, 1989. ,
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29in vitro andin vivo, International Journal of Cancer, vol.74, issue.5, pp.729-734, 1997. ,
DOI : 10.1002/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line, Biochemical Pharmacology, vol.55, issue.5, pp.667-676, 1998. ,
DOI : 10.1016/S0006-2952(97)00541-8
Sequence dependent growth inhibition and DNA damage formation by the irinotecan-5fluorouracil combination in human colon carcinoma cell lines, Eur J Cancer, vol.13, pp.1851-1861, 1999. ,
Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer, American Journal of Clinical Oncology, vol.26, issue.3, pp.254-258, 2003. ,
DOI : 10.1097/01.COC.0000020581.59835.7A
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer, British Journal of Cancer, vol.57, issue.10, pp.1536-1541, 2010. ,
DOI : 10.1200/JCO.2009.25.1991
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance, Journal of Clinical Oncology, vol.28, issue.3, pp.453-459, 2010. ,
DOI : 10.1200/JCO.2009.24.8252
Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal Cancer, Seminars in Oncology, vol.33, pp.8-14, 2006. ,
DOI : 10.1053/j.seminoncol.2006.08.005
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study, Journal of Clinical Oncology, vol.25, issue.30, pp.4779-4786, 2007. ,
DOI : 10.1200/JCO.2007.11.3357
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study, Annals of Oncology, vol.20, issue.11 ,
DOI : 10.1093/annonc/mdp233
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5727-5733, 2009. ,
DOI : 10.1200/JCO.2009.23.4344
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for fi rst-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet Oncol, vol.12, pp.542-553, 2011. ,
Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.4010
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study, The Oncologist, vol.17, issue.1, pp.15-25, 2012. ,
DOI : 10.1634/theoncologist.2011-0249
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates, Annals of Oncology, vol.16, issue.8, pp.1311-1319, 2005. ,
DOI : 10.1093/annonc/mdi246
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, The Lancet Oncology, vol.11, issue.9, pp.845-852, 2010. ,
DOI : 10.1016/S1470-2045(10)70175-3
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer, British Journal of Cancer, vol.10, issue.1, pp.51-59, 2011. ,
DOI : 10.1016/j.bbrc.2005.06.014
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia, Leukemia, vol.93, issue.9, pp.1901-1906, 2007. ,
DOI : 10.1016/j.ccr.2004.09.030
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma, Clinical Cancer Research, vol.15, issue.4, pp.1384-1392, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1615
Phase III RANDOMIZED Trial of FOLFIRI Versus FOLFOX4 in the Treatment of http, pp.1471-2407611 ,
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial, Annals of Oncology, vol.22, issue.5, pp.1236-1242, 2011. ,
DOI : 10.1093/annonc/mdq580
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, The Lancet, vol.370, issue.9582, pp.135-142, 2007. ,
DOI : 10.1016/S0140-6736(07)61086-1
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000???05): an open-label, randomised, phase 3 trial, The Lancet Oncology, vol.12, issue.11, pp.1032-1044, 2011. ,
DOI : 10.1016/S1470-2045(11)70199-1
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, The Lancet, vol.377, issue.9783, pp.2103-2114, 2011. ,
DOI : 10.1016/S0140-6736(11)60613-2
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study, Journal of Clinical Oncology, vol.26, issue.12, pp.2013-2019, 2008. ,
DOI : 10.1200/JCO.2007.14.9930
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III), Journal of Clinical Oncology, vol.30, issue.29, pp.3588-3595, 2012. ,
DOI : 10.1200/JCO.2012.42.5355
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1417, 2009. ,
DOI : 10.1056/NEJMoa0805019
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-4705, 2010. ,
DOI : 10.1200/JCO.2009.27.4860
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.22, issue.7, pp.1535-1546, 2011. ,
DOI : 10.1093/annonc/mdq632
Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis, JNCI Journal of the National Cancer Institute, vol.103, issue.1, pp.21-30, 2011. ,
DOI : 10.1093/jnci/djq456
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels, BMC Cancer, vol.103, issue.1, p.611, 2013. ,
DOI : 10.1093/jnci/djq456
URL : https://hal.archives-ouvertes.fr/inserm-00922823